Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma
- PMID: 25687653
- DOI: 10.1038/leu.2015.43
Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma
Abstract
Prognostically relevant risk factors in patients with diffuse large B-cell lymphoma (DLBCL) have predominantly been evaluated in elderly populations. We tested whether previously described risk factors are also valid in younger, poor-prognosis DLBCL patients. Paraffin-embedded samples from 112 patients with de novo DLBCL, enrolled in the R-MegaCHOEP trial of the German High Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) were investigated using immunohistochemistry (MYC, FOXP1, LMO2, GCET1, CD5, CD10, BCL2, BCL6, IRF4/MUM1) and fluorescence in situ hybridization (MYC, BCL2, BCL6). MYC, BCL2 and BCL6 breaks occurred in 14, 21 and 31%, respectively. In the majority of cases, MYC was simultaneously rearranged with BCL2 and/or BCL6. The adverse impact of MYC rearrangements was confirmed, but the sole presence of BCL2 breaks emerged as a novel prognostic marker associated with inferior overall survival (OS) (P=0.002). Combined overexpression of MYC and BCL2 showed only limited association with inferior OS. All immunohistochemical cell of origin classifiers applied failed to predict survival time. DLBCL tumors with significant proportion of immunoblastic and/or immunoblastic-plasmacytoid cells had inferior OS, independently from from BCL2 break. Younger, poor-prognosis DLBCL patients, therefore, display different biological risk factors compared with an elderly population, with BCL2 translocations emerging as a powerful negative prognostic marker.
Similar articles
-
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.J Clin Oncol. 2017 Aug 1;35(22):2515-2526. doi: 10.1200/JCO.2016.70.3660. Epub 2017 May 19. J Clin Oncol. 2017. PMID: 28525305 Clinical Trial.
-
Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.PLoS One. 2017 Oct 31;12(10):e0186983. doi: 10.1371/journal.pone.0186983. eCollection 2017. PLoS One. 2017. PMID: 29088292 Free PMC article.
-
Clinical Significance of BCL2, C-MYC, and BCL6 Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients.Int J Med Sci. 2019 Apr 20;16(4):556-566. doi: 10.7150/ijms.27610. eCollection 2019. Int J Med Sci. 2019. PMID: 31171907 Free PMC article.
-
The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.Acta Haematol. 2020;143(6):520-528. doi: 10.1159/000505892. Epub 2020 Feb 19. Acta Haematol. 2020. PMID: 32074595 Review.
-
Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.Eur J Cancer. 2016 Mar;55:140-6. doi: 10.1016/j.ejca.2015.12.001. Epub 2016 Jan 25. Eur J Cancer. 2016. PMID: 26820684 Review.
Cited by
-
[Revised version of the 4th edition of the WHO classification of malignant lymphomas : What is new?].Pathologe. 2019 Mar;40(2):157-168. doi: 10.1007/s00292-018-0456-4. Pathologe. 2019. PMID: 30019203 Review. German.
-
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.Clin Cancer Res. 2022 Mar 1;28(5):972-983. doi: 10.1158/1078-0432.CCR-21-2949. Clin Cancer Res. 2022. PMID: 34980601 Free PMC article.
-
Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.Medicine (Baltimore). 2015 Dec;94(52):e2388. doi: 10.1097/MD.0000000000002388. Medicine (Baltimore). 2015. PMID: 26717387 Free PMC article.
-
DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.PLoS One. 2019 Aug 16;14(8):e0220681. doi: 10.1371/journal.pone.0220681. eCollection 2019. PLoS One. 2019. PMID: 31419226 Free PMC article.
-
Clinicopathological Analysis of 320 Cases of Diffuse Large B-cell Lymphoma Using the Hans Classifier.J Clin Exp Hematop. 2017;57(2):54-63. doi: 10.3960/jslrt.17029. J Clin Exp Hematop. 2017. PMID: 29021515 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources